Strengthening Existing Businesses and Investing in New Businesses Through Retained Earnings
First written in FY2016. 14 of 15 entries say "Restated". Latest entry: FY2025-H1.
- FY2025-H1RestatedAnnual report
「The group funds short-term working capital and long-term investments with cash on hand, and there were no material changes during the interim consolidated accounting period.」
The company has reaffirmed that there have been no material changes to its policy of funding short-term working capital and long-term investments with cash on hand. - FY2024-Q1RestatedAnnual report
「There are no plans to change the allocation of funds to growth investment, cash on hand and shareholder returns in light of the impact of the novel coronavirus disease.」
The company has reaffirmed that it has no plans to change its policy for allocating funds to growth investment, cash on hand and shareholder returns in light of the impact of the infectious disease. - FY2023-Q3RestatedAnnual report
「There are no plans to change the allocation of funds to growth investment, cash on hand and shareholder returns in light of the impact of the novel coronavirus disease.」
The company has stated that it will not change its policy for allocating funds to growth investment, cash on hand and shareholder returns even amid the impact of the infectious disease. - FY2023-Q2RestatedAnnual report
「There are no plans to change the allocation of funds to growth investment, cash on hand and shareholder returns in light of the impact of the novel coronavirus disease.」
The company has stated that it will not change its policy for allocating funds to growth investment, cash on hand and shareholder returns even amid the impact of the infectious disease. - FY2023-Q1RestatedAnnual report
「There are no plans to change the allocation of funds to growth investment, cash on hand and shareholder returns in light of the impact of the novel coronavirus disease.」
The company has stated that it will not change its policy for allocating funds to growth investment, cash on hand and shareholder returns even amid the impact of the infectious disease. - FY2022RestatedAnnual report
「Retained earnings will be allocated to preparing for future business development and to research and development expenses.」
The company continues to pursue a policy of allocating retained earnings to future business development and research and development. - FY2022-Q3RestatedAnnual report
「There are no plans to change the allocation of funds to growth investment, cash on hand and shareholder returns in light of the impact of the novel coronavirus disease.」
The company has stated that it will not change its policy for allocating funds to growth investment, cash on hand and shareholder returns even amid the impact of the infectious disease. - FY2022-Q2RestatedAnnual report
「There are no plans to change the allocation of funds to growth investment, cash on hand and shareholder returns in light of the impact of the novel coronavirus disease.」
The company has stated that it will not change its policy for allocating funds to growth investment, cash on hand and shareholder returns even amid the impact of the infectious disease. - FY2022-Q1RestatedAnnual report
「There are no plans to change the allocation of funds to growth investment, cash on hand and shareholder returns in light of the impact of the novel coronavirus disease.」
The company has stated that it will not change its policy for allocating funds to growth investment, cash on hand and shareholder returns even amid the impact of the infectious disease. - FY2021-Q3RestatedAnnual report
「There are no plans to change the allocation of funds to growth investment, cash on hand and shareholder returns in light of the impact of the novel coronavirus disease.」
The company has stated that it will not change its policy for allocating funds to growth investment, cash on hand and shareholder returns even amid the impact of the infectious disease. - FY2021-Q2RestatedAnnual report
「There are no plans to change the allocation of funds to growth investment, cash on hand and shareholder returns in light of the impact of the novel coronavirus disease.」
The company has stated that it will not change its policy for allocating funds to growth investment, cash on hand and shareholder returns even amid the impact of COVID-19. - FY2021-Q1RestatedAnnual report
「There are no plans to change the allocation of funds to growth investment, cash on hand and shareholder returns in light of the impact of the novel coronavirus disease.」
The company has stated that it will not change its policy for allocating funds to growth investment, cash on hand and shareholder returns even amid the impact of the infectious disease. - FY2019RestatedAnnual report
「Retained earnings will be allocated to preparing for future business development and to research and development expenses.」
The company continues to pursue a policy of allocating retained earnings to future business development and research and development. - FY2017RestatedAnnual report
「Retained earnings will be allocated to preparing for future business development and to research and development expenses.」
The company continues to pursue a policy of allocating retained earnings to future business development and research and development. - FY2016First statedAnnual report
「We will continue working to improve performance and maximize shareholder returns by strengthening existing businesses and investing in new businesses using retained earnings, with the aim of increasing the corporate value of the group as a whole.」
The company has indicated a policy of allocating retained earnings to existing and new businesses alongside stable dividends.